October 13 - 14, 2020 | San Francisco, California
Missed the 2019 BIO Investor Forum? Sign up for the Virtual Attendee Package and gain access to recorded video of 12 educational sessions, including panel discussions and fireside chats.
Tuesday, October 22
|
6:30am - 5:00pm |
Registration |
|
7:00am - 7:55am |
Networking Breakfast |
|
7:20am - 5:30pm |
Satellite Partnering Desk |
|
7:30am - 5:30pm |
Partnering Meetings |
|
8:30am - 4:55pm |
Company Presentations |
|
8:30am - 9:40am |
The Next Wave of Cancer Treatments: Allogenic Cell Therapies and Other Pioneers |
|
9:45am - 10:40am |
Private Investors' Incubators for University-Sourced Ideas |
|
10:45am - 11:40am |
Gene Therapies: Pipelines Into A New Era for Patients |
|
12:00pm - 12:30pm |
Networking Lunch |
|
12:30pm - 12:45pm |
Plenary - BIO's President and CEO Jim Greenwood presents a Policy Update |
|
12:45pm - 1:40pm |
Plenary - Public Policy Outlook on Biotech Investment from China |
|
2:00pm - 2:55pm |
Fireside Chat: Lon Cardon, PhD, Chief Scientific Strategy Officer, BioMarin |
|
3:00pm - 3:55pm |
Recruiting Talent to Meet Corporate Board Requirements and Representation Goals |
|
4:00pm - 4:55pm |
View from the Board: Making an Acquisition Offer |
|
5:30pm - 6:30pm |
Opening Reception |
Wednesday, October 23
|
7:00am - 7:55am |
Networking Breakfast |
|
7:00am - 4:30pm |
Registration |
|
7:00am - 5:00pm |
Partnering Meetings |
|
8:30am - 4:55pm |
Company Presentations |
|
8:30am - 9:40am |
Progress in CNS Drug Development Outside Dementia |
|
9:45am - 10:40am |
Advice on Pitching to Family Offices, Venture Philanthropies, and Other Non-VC Funding Sources |
|
10:45am - 11:40am |
Molecular Diagnostics: Drivers of New Investor Interest and Reimbursement Success |
|
12:00pm - 1:25pm |
Fireside Chat: Wende Hutton, General Partner, Canaan |
|
1:45pm - 2:40pm |
Separating Artificial Intelligence Hype from Real Utility in Drug Development |
|
2:45pm - 3:55pm |
Best Practices in Biopharma Alliances with Digital Therapeutics Partners |
|
4:00pm - 4:55pm |
Market Outlook - Taking the Temperature of the IPO Market in an Era of Large Pharma M&A |
Statement on Diversity
BIO is committed to workforce development, diversity, and inclusion, and incorporates these values into all aspects of BIO operations. Program development for BIO’s events will be considered in this light, with specific attention paid to speakers’ gender, race, ethnic background, sexual orientation, and gender identity, as well as their company’s focus, financing, geographic location, and size. Diverse programming at BIO’s events allows BIO to remain a strong leader in efforts to ensure that the biotechnology industry can attract, develop, and retain a high-quality, globally competitive employee talent pool. Learn more about Workforce Development, Diversity, & Inclusion at BIO.